GENERIC NAME: ombitasvir, paritaprevir, ritonavir, and dasabuvir
BRAND NAME: Viekira Pak
DRUG CLASS AND MECHANISM: Viekira Pak is a combination of drugs used to treat patients with hepatitis C virus (HCV) genotype 1. It contains four medicines, dasabuvir, ombitasvir, paritaprevir, and ritonavir. Viekira Pak belongs to a class of drugs called direct-acting antiviral agents. Similar drugs include
- boceprevir (Victrelis),
- sofosbuvir (Sovaldi),
- simeprevir (Olysio),
- telaprevir (Incivek), and
- ombitasvir, paritaprevir, ritonavir (Technivie).
Dasabuvir, ombitasvir, and paritaprevir are antivirals that work in three different ways to help stop HCV from multiplying. They block the effect of proteases which are enzymes that HCV uses for making new virus, leading to reduced numbers of HCV copies in the body. Ombitasvir blocks HCV NS5A protease while paritaprevir blocks HCV NS3/4A protease. Dasabuvir blocks a viral structure called NS5B palm polymerase which is also needed for replication of HCV. Ritonavir is not active against the HCV virus. It is used to increase blood levels of paritaprevir by inhibiting the breakdown of paritaprevir.
In clinical studies Viekira Pak, with or without ribavirin (Rebetol) HCV was cured in 95% to 100% of patients treated. Cure was defined as undetectable levels of HCV in the blood 3 months after treatment. The FDA approved Viekira Pak in December 2014.
PRESCRIBED FOR: Viekira Pak is a used with or without ribavirin to treat patients with genotype 1 chronic HCV infection, including those who have compensated cirrhosis.
Quick GuideHepatitis C (Hep C) Symptoms and Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.